More recently, it has been shown that PHLPP expression decreased in proteasome inhibitor bortezomib-resistance cells and bone marrow sample of patients with multiple myeloma, and overexpression of PHLPP partially increased bortezomib sensitivity in multiple myeloma cell lines (36). The gene discussed is PHLPP1; the disease is plasma cell myeloma.